Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates


Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML

Visit link:
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Related Posts